This is a preview of subscription content, log in via an institution to check access.
Reference
Li N, et al. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Frontiers in Pharmacology : 20 Apr 2021. Available from: URL: http://doi.org/10.3389/fphar.2021.632818
Rights and permissions
About this article
Cite this article
Olaparib for germline BRCA-mutated metastatic pancreatic cancer: cost effective in China and US. PharmacoEcon Outcomes News 878, 22 (2021). https://doi.org/10.1007/s40274-021-7708-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7708-x